Home › Research › Drug development
Japanese Clinical Practice Guideline for Diabetes 2019
Eiichi Araki, Atsushi Goto, Tatsuya Kondo, Mitsuhiko Noda, Hiroshi Noto, Hideki Origasa, Haruhiko Osawa, Akihiko Taguchi et al.. Journal of Diabetes Investigation, 2020-07-01
Topic: Gut, metabolism and diet
Of note, dramatic progress has been made in recent years in diabetes research and clinical practice, which includes approval of antidiabetic agents with novel mechanisms of action along with publication of clinical trial results with these drugs, and novel diagnostic and therapeutic devices, such as continuous glucose monitoring (CGM) and sensor augmented pumps (SAP). Again, results from large-scale clinical trials in Japan, such as J-DOIT 1 to 3 and JDCP studies, have recently been reported. The grade of recommendation was determined by each CGC member with consideration given to certainty of overall evidence, balance of benefits and harms, patient preferences/values, and costs (Table 2). The onset of fulminant type 1 diabetes may be associated with pregnancy. For elderly patients, the coefficient could be made larger than that associated with their actual level of physical activity to prevent them from developing frailty. Conversely, for obese patients in a weight loss program, the coefficient could be made lower than that associated with their actual level of physical activity. To ensure long-term implementation of MNT in patients with diabetes, priority is to be given to honoring their eating habits and preferences thus allowing them to enjoy their meals as far as they do not defeat the purpose of MNT medically, while at the same time giving consideration to any potential risks associated with their individual diet regimens. Disadvantage: Adjusted for average body surface area (BSA) (1.73 m2), the formula is likely to be associated with a greater estimation error in patients of large and small build. The formula is also associated with overestimated values in patients with low muscle mass. Disadvantage: Adjusted for average BSA (1.73 m2), the formula is also likely to be associated with a greater estimation error in patients of large and small build. (Figure 7) GDM is diagnosed if one or more of the following criteria have been met in a 75 g OGTT: ① Fasting blood glucose value ≥92 mg/dL ② 1-h post-OGTT glucose value ≥180 mg/dL ③ 2-h post-OGTT glucose value ≥153 mg/dL Overt diabetes in pregnancy is diagnosed if ① or ② below has been met: ① Fasting blood glucose value ≥126 mg/dL ② HbA1c ≥6.5% ① Diabetes mellitus diagnosed before pregnancy ② Pregnancy associated with unequivocal evidence of diabetic retinopathy <5.3 mmol/L*4 (<95 mg/dL) 1-h PPG <140 mg/dL Or 2-h PPG <120 mg/dL 1-h PPG <140 mg/dL Or 2-h PPG <120 mg/dL 1-h PPG <7.8 mmol/L (<140 mg/dL) Or 2-
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., et al. (2020). Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.13306
Vancouver
Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation. 2020. doi:10.1111/jdi.13306.
BibTeX
@article{araki2020-7f71ce0b,
author = {Araki, Eiichi and Goto, Atsushi and Kondo, Tatsuya and Noda, Mitsuhiko and Noto, Hiroshi and Origasa, Hideki and Osawa, Haruhiko and Taguchi, Akihiko and others},
title = {{Japanese Clinical Practice Guideline for Diabetes 2019}},
journal = {Journal of Diabetes Investigation},
year = {2020},
doi = {10.1111/jdi.13306},
url = {https://doi.org/10.1111/jdi.13306}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Of note, dramatic progress has been made in recent years in diabetes research and clinical practice, which includes approval of antidiabetic agents with novel mechanisms of action along with publication of clinical trial results with these drugs, and novel diagnostic and therapeutic devices, such as continuous glucose monitoring (CGM) and sensor augmented pumps (SAP).
- Again, results from large-scale clinical trials in Japan, such as J-DOIT 1 to 3 and JDCP studies, have recently been reported.
- The grade of recommendation was determined by each CGC member with consideration given to certainty of overall evidence, balance of benefits and harms, patient preferences/values, and costs (Table 2).
- The onset of fulminant type 1 diabetes may be associated with pregnancy.
- For elderly patients, the coefficient could be made larger than that associated with their actual level of physical activity to prevent them from developing frailty.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designrandomized controlled trial
- Effect size6.5%
- Evidence strengthHigh
How this study scored 71/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for sample size and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 41 of the 58 points we could judge it on, which is 71 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Diabetes Investigation) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomised controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 41 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 41 of the 58 points we could judge it on is 71 out of 100. |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Drug development
Also tagged “deaths”
109 studies in the library carry the topic tag “deaths”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 109 tagged studies.